A Phase I Study of Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer (OPERA-RADIO)
Latest Information Update: 01 Nov 2024
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Gastrointestinal cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms OPERARADIO
Most Recent Events
- 29 Oct 2024 Planned End Date changed from 1 Jun 2026 to 1 Jul 2029.
- 29 Oct 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jul 2025.
- 29 Oct 2024 Status changed from recruiting to active, no longer recruiting.